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Background: Chronic pancreatitis is characterized by progressive fibrosis, pain and loss of exocrine and endocrine
functions. The long-standing chronic pancreatitis and its associated pancreatic fibrosis are the most common
pathogenic events involved in human pancreatic carcinogenesis, but the therapeutic strategies to chronic
pancreatitis and the chemoprevention of pancreatic carcinogenesis are very limited.
Methods: We investigated the effect of sulindac, a non-steroidal anti-inflammatory drug (NSAID), on inhibition of
chronic pancreatitis in a caerulein induced chronic pancreatitis mouse model.
Results: Sulindac significantly reduced the severity of chronic pancreatitis including the extent of acini loss,
inflammatory cell infiltration and stromal fibrosis. The protein expression of phosphorylation of MEK/ERK was
inhibited in the chronic pancreatic tissues by sulindac treatment as measured by Western blot assay. The levels of
inflammatory cytokines including TNF-α and MCP-1 were also significantly decreased with sulindac treatment,
as well as the expression of TGF-β, PDGF-β, SHH and Gli in the chronic pancreatic tissue detected by qPCR assay
and confirmed by western blot assay. The activation of pancreatic satellet cells was also inhibited by sulindac as
measured by the activity of α-smooth muscle actin (α-SMA) in the pancreatic tissue of chronic pancreatitis.
Conclusions: Sulindac is a promising reagent for the treatment of chronic pancreatitis via inhibition of
inflammatory cell infiltration and stromal fibrosis, the inhibitory effect of sulindac on chronic pancreatitis may
through targeting the activation ERK/MAPK signaling pathway.
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Chronic pancreatitis (CP) is a disease with a succession
of pathophysiological events including inflammatory
cell infiltration, parenchymal atrophy, and extensive
fibrosis of the exocrine pancreas [1]. The pathophysi-
ology of chronic pancreatitis is not completely under-
stood, although a number of advances have been made
in recent years. The most accepted theory is that
repeated acute attacks of pancreatic necro-inflammation
together with a dysregulated ability to repair organ* Correspondence: douxg@sj-hospital.org
1Department of Infectious Disease, Shengjing Hospital of China Medical
University, Shenyang 110004, China
Full list of author information is available at the end of the article
© 2012 Bai et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordamage leads to activation of a fibrotic cascade and loss
of parenchymal mass [2].
Pancreatic stellate cells (PSCs) play a crucial role in
the initiation and progression of pancreatic fibrogenesis
in chronic pancreatitis [3]. When PSCs are stimulated
by the profibrogenic mediators, the quiescent cells con-
verts to a myofibroblast-like, alpha smooth muscle actin
(a-SMA)-positive cells that is highly proliferative and
capable of depositing fibrillar collagen in the interstitial
spaces [4]. PDGF and TGF have been shown to have a
significant impact on the activity of PSCs that are gener-
ated by inflammatory cells [5]. PDGF appears to be a
potent mitogen and chemoattractant for PSC, whereas
TGF-β stimulates PSCs to synthesize and secrete matrixThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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laminin, and MMP 2, 3 and 13 [6-8].
Hedgehog signal is frequently activated in fibrogenic
pancreatic diseases such as chronic pancreatitis [9],
the molecules of Hedgehog pathway are frequently up-
regulated in the conditions of these diseases, which indi-
cated that hedgehog signal is involved in pancreatic
fibrogenesis, and enhanced migration of pancreatic stel-
late cells maybe one of the mechanisms [10].
Despite the better understanding of its mechanisms,
the therapeutic strategies to CP are mostly symptomatic
and very limited. Cycloxygenase (COX) is a key enzyme
in the synthesis of prostaglandins (PGs) from arachi-
donic acid [11]. Elevated COX-2 levels have been identi-
fied both in pancreatic tissue from patients with chronic
pancreatitis and animal model of chronic pancreatitis
[12-14]. PGE2 is a known proinflammatory molecule
that has been studied in many chronic diseases, includ-
ing pain, osteoarthritis, and rheumatoid arthritis [15-17],
as well as in cancer [18,19], and hence providing a
potential target for the treatment of CP. COX-2 inhibi-
tors, inhibit the activities of cyclooxygenases (COXs),
significantly suppresse inflammation and fibrosis and
delay the progression of the diseases [1,14,20,21]. Sulin-
dac is a non-steroidal anti-inflammatory drug (NSAID)
of the arylalkanoic acid class that, in vivo, is reversibly
converted into its anti-inflammatory active compound,
sulindac sulfide, with the biological effects of inhibition
on both cyclooxygenase-1 (COX-1) and COX-2 activities
and reduction in prostaglandin (PG) synthesis [22].
There are several animal models for chronic pancrea-
titis, repeatedly caerulein intraperitoneal injection induced
mice chronic pancreatitis is one of the best characterized
chronic pancreatitis mouse model [23,24]. Caerulein is a
cholecystokinin analog that is commonly used to induce
either acute or chronic pancreatitis. Cholecystokinin is a
major physiologic regulator of digestive enzyme secretion
by the pancreatic acinar cell , however, supramaximal
stimulation by cholecystokinin and its analogs could gen-
erate a distinct pancreatic response that includes dimin-
ished secretion, accumulation of secretory proteins within
the pancreas and cause pancreatic injury [25], Chronic
fibrotic changes in the pancreas are to perform self-
limited acute acinar cell injury by repeated pathological
stimuli of the gland by caerulein [26]. This method
mimics the clinical observation that repeated episodes
of acute pancreatitis, irrespective of its origin, lead to
increasing damage of the organ that eventually results in
atrophy and fibrosis [3]. The induction of acute or
chronic pancreatitis by caerulein depends on the schedule
and the dose administrated [24,27].
In the present study, we examined the therapeutic ef-
fect of sulindac on chronic pancreatitis using caerulin-
induced chronic pancreatitis mouse model, the effect ofsulindac on the development of chronic pancreatitis was
examined. Systemically histopathologic and immunohis-
tochemical analysis of chronic pancreatitis, and chronic
inflammation activated signals were also performed.
Materials and methods
Animal experiment
Thirty C57BL/6 mice of 6–8 weeks old were obtained
from Shanghai Experimental Center of Chinese Acad-
emy of Science (Shanghai, China). Mice were housed
under pathogen-free conditions with free access to water
and lab chow in the facilities of Laboratory Animal
Services, Shengjing Hospital of China Medical Univer-
sity. After 1 week of new arrival, the mice were enrolled
in the experiment with both genders. All studies were
conducted in compliance with the China Medical Uni-
versity Institutional Animal Care and Use Committee
(IACUC) guidelines.
Sulindac (purity ≥ 98%) and caerulein (purity ≥ 97% by
HPLC) were purchased from Sigma Aldrich (Shanghai,
China). Based on literatures, Chronic pancreatitis was
induced by repeated intraperitoneal (IP) injections of
caerulein with 50 μg/kg every hour for 6 hours, twice
weekly, for 10 weeks in 20 mice, 10 mice treated with
saline IP injected instead of caerulein were as control
[26]. AIN-76A diet (control diet) and AIN-76A diet sup-
plemented with 200 ppm sulindac (sulindac diet) were
from Trophic animal feed high-tech Co., Ltd. (Nantong,
China). All mice received AIN-76A diet for the first
2 weeks after caerulein injection, and then the mice were
administrated with either sulindac diet (10 caerulein
treated mice and 5 control mice) or control diet (10
caerulein treated mice and 5 control mice) for 8 weeks
with free access to water. The dose of sulindac used in
this study was based on the literature [28] and the previ-
ous experience of study on sulindac in our lab. The diets
were replenished every 3 days, food and water consump-
tion were monitored every day and body weight was
measured weekly.
Tissue Preparation and histological analysis of chronic
pancreatitis
At the end of the experiment, the mice were sacrificed
by CO2 asphyxiation; pancreases and other key organs
such as liver and spleen were collected and weighted.
Half of the pancreas was fixed in 10% buffered formalin
for 24 h, routinely processed, and embedded in paraffin,
the other part were stored freshly at −80°C for protein
and RNA assay. Serial paraffin sections (5 μm) were
made and stained with hematoxylin and eosin (H&E) for
histopathological examination. Additional tissue sections
were obtained on poly-L-lysine coated slides for histo-
chemical staining (Masson Trichrome) and immunohis-
tochemical staining.
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using a semi-quantitative scoring system according to
our published paper [29]. The criteria for chronic
pancreatitis scoring were summarized in table 1. The
chronic pancreatitis index (CPI) was expressed as a sum
of scores on loss of acini, inflammatory cell infiltration
and stromal fibrosis. The extent or areas of loss of acini
were evaluated of the whole pancreas area; the number
of inflammatory cells infiltration was measured for at
least 10 non-overlapping and randomly selected fields
per high power field (40X objective lens) and the area
and intensity of stromal fibrosis of the pancreas was
graded based on Masson Trichrome staining.
Immunohistochemical analysis
Immunohistochemical staining was performed according
to the routine protocol using an avidin-biotin-peroxidase
method [30]. Briefly, Sections were deparaffinized and
rehydrated, the sections were then boiled with antigen
unmasking solution to retrieve the antigens, and were
quenched with 3% hydrogen peroxide. After blocked
with normal serum, the sections were incubated with
one of the primary antibodies including rabbit polyclonal
anti-myeloperoxidase (MPO) antibody (dilution 1:35; Abcam,
Cambridge, Massachusetts, USA.), rat anti-murine Mac-3
monoclonal antibody (dilution 1:20; Novus Biologicals,
CO, USA), rabbit monoclonal anti-phospho-ERK1/2
(dilution 1:100; Cell Signaling Technology, Boston,
Massachusetts, USA) antibody at 4°C over night. Then
after incubation with the appropriate biotinylated second-
ary antibody (dilution 1:200) and avidin-biotin-peroxidase
complex, a characteristic brown color was developed by
incubation with 3, 3-diaminobenzidine substrate chromo-
gen system (Sigma-Aldrich, Shanghai, China).
A sequential method for Amylase/CK-19 double stain-
ing was used according to the immunohistochemistry
enzyme double staining protocol [31]. Same as described
above, the sections were incubated with goat polyclonal
anti-CK19 antibody (dilution 1:50; Santa Cruz Biotech-
nology, Santa Cruz, California, USA) as the first primary
antibody and detected by DAB substrate chromogen
system (Sigma-Aldrich). the sections were then blocked
again with normal serum, and incubated with the second
primary antibody, mouse monoclonal anti-Amylase anti-
body (dilution 1:50; Santa Cruz Biotechnology, SantaTable 1 Scoring criteria for grade of chronic pancreatitis
Extent or areas





0 absent <5/High power field absent
1 <10% 5-50/High power field <5%
2 10-30% 50-100/High power field 5-15%
3 >30% >100/High power field >15%Cruz, California, USA), after incubating with the anti-
mouse secondary antibody and avidin-biotin-peroxidase
complex, 3-amino-9-ethylcarbazole (AEC) peroxidase
substrate with a characteristic red color was used to
detect the positive staining and distinguish from the
brown color of DAB.
The negative control was established by replacement
of primary antibody with normal serum, and appropriate
positive control was used for each primary antibody.
Specific antibody-labeled signals were analyzed under
Nikon research microscope.
Quantitative real-time PCR Assay
Total RNA was extracted from fresh pancreatic tissue
using RNeasyW mini kit (Qiagen, Inc., Valencia, CA,
USA). RNA concentration was determined using a
SmartSpec Plus Spectrophotometer (BioRad, Hercules,
CA, USA). First-strand cDNA was synthesized using
1 μg of total RNA in a 20 μl reverse transcriptase reac-
tion mixture using iScriptTM cDNA synthesis kit (BioRad)
according to the manufacturer’s instructions. The regions
of Tumor necrosis factor α(TNF- α), Monocyte chemo-
tactic protein 1 (MCP-1), Transforming growth factor β
(TGF-β), Platelet derived growth factor β (PDGF-β),
Sonic hedgehog homolog (Shh) and Glioma-associated
oncogene homolog 1 (GLI1), and also alpha-smooth
muscle actin (α-SMA) mRNA were amplified using the
following primers shown in table 2 which were designed
using the primer 3 software. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as internal control.
All Real-Time PCR reactions were performed in a 20 μl
mixture containing 1/10 volume of cDNA preparation
(2 μl), 10 μl iQTM SYBRW Green supermix (BioRad),
0.5 μM of each primer and 8 μl diethylprocarbonate
(DEPC) water. Real-time quantitation was performed
using the MiniOpticon Real-Time PCR System (BioRad).
PCR conditions were: 50°C for 2 minutes, 95°C for 2 min-
utes, followed by 40 cycles of 95°C, 15 sec; 58°C, 3 sec;
50°C, 1 sec. Data of each mRNA expression were shown
as the relative folds of change normalized by that of
GAPDH.
Protein extraction and Western blot assay
Freshly harvested pancreases were homogenized and
lysed in ice-cold RIPA lysis buffer (Santa Cruz) for
60 minutes by vortexing every 5 min. The lysates were
separated by centrifugation at 14,000 × g for 10 minutes
at 4°C. The supernatants were collected, aliquot, and
stored at −80°C until Western blot assay conducted.
All protein concentrations were determined using the
Bradford reagent.
30 μg of the total protein per lane was separated by
10% or 12% SDS-PAGE gel based on the molecular
weight of the target proteins , and were then transferred
Table 2 Primer Sequences of Genes Evaluated by Real-time Quantitative PCR
Gene Forward sequence Reverse sequence
TNF-α 5’-CCAACGGCATGGATCTCAAAGACA 5’-TGAGATAGCAAATCGGCTGACGGT
MCP-1 5’-ACTGAAGCCAGCTCTCTCTTCCTC 5’-TTCCTTCTTGGGGTCAGCACAGAC
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blocking with 5% bovine serum albumin (BSA) in 1X
Tris-Buffered Saline with 0.1% Tween-20 (TBST) or 5%
non-fat milk in TBST, the membranes were incu-
bated with one of the following primary antibodies,
including anti-phosphorate-MEK/anti-MEK, anti-phospho-
rate-ERK/anti-ERK, anti-TNF-α, anti-TGF- β, anti-PDGF- β,
anti-MCP-1, anti-Shh and anti-GLI1 antibodies (all of the
above with dilution 1:1000, Cell Signaling), and anti-α-
SMA antibody (dilution 1:200; Abcam, Cambridge, Mas-
sachusetts, USA) at 4°C overnight. The membranes were
then incubated with horseradish peroxidase (HRP)-
linked anti-rabbit IgG or anti-mouse IgG, according to
the origin of the primary antibodies, (dilution 1:2000,
Cell Signaling) for 1 hour at room temperature (RT). Be-
tween the steps, the membrane was washed with TBST
for 5 minutes by 3 times. The protein-antibody complex
was detected by using the chemiluminescent substrate
(Cell Signaling) according to the manufacturer's instruc-
tions; the emitted light was captured on an X-ray film.
Statistical analysis
Each analyzed parameter was expressed as Mean ± SD,
unless otherwise stated. Continuous variables were com-
pared with the Student’s t-test, whereas categorical vari-
ables were compared with Chi-square test. All statistical
tests were two-sided, statistical significance was taken as
p < 0.05.
Results
Sulindac attenuated caerulein induced chronic
pancreatitis in mice
Sulindac was administered in diet for 8 weeks in this
study. The average daily food consumption per mice in
our experiment is about 2.6 g, the average body weight
of the mice was 25.5 g, and therefore the administrated
dose of sulindac per mice was about 0.5 ± 0.1 mg/day or
20 mg/kg/day. All of the Animals showed steady body
weight gain during the course of the experiment. There
was no significant difference of body weight in mice
between caerulein induced chronic pancreatitis groupand the control group, or in the mice with or without
sulindac treatment. None of the animals with sulindac
administration exhibited any observable toxicity or any
gross changes attributable to the change in liver, spleen,
kidney or lung. There were also no differences of water
and food consumption among the treatment and control
group (Figure 1).
Hematoxylin-eosin stained slides revealed no pancrea-
titis in control mice either with or without sulindac
treatment (Figure 2A). Repeatedly caerulein treated mice
exhibited extensive chronic pancreatitis as seen in
Figure 2B, including multi-focal patterns of acinar loss,
stromal fibrosis, and inflammatory cell infiltration.
Marked decrease improvement of chronic pancreatitis
was observed in mice treated with sulindac (Figure 2C).
Acinar loss and ductular proliferation were further
analyzed using amylase and cytokeratin 19 (CK19)
double immunohistochemical approache. In normal
pancreas, amylase-labeled acinar cells were composed of
about 80% of pancreatic parenchyma, and only about 2%
was CK19 positive pancreatic ductal tissues (Figure 2D).
A marked loss of amylase positive acinar tissues and an
increase of CK19 positive ductal tissues were displayed in
caerulein induced chronic pancreatitis mice (Figure 2E).
Sulindac treatment significantly increased the amylase
positive area of acini tissues and decreased the CK19
positive area of ductal tissues in the pancreas (Figure 2F).
Semi-quantitative analysis of the amylase or CK19 posi-
tive area revealed that the average of the extent or loss of
acina score was 2.33 ± 0.54 in caerulein induced chronic
pancreatitis, it decreased to 1.66 ± 0.67 with sulindac
treatment (Figure 3A, P< 0.05).
Masson Trichrome histochemical stain highlighted
stromal fibrosis in chronic pancreatitis. The pancreas in
control mice only showed positive trichrome’s staining
in the interlobular fibro-connective tissue (Figure 2G).
Extensive Trichrome positive staining was observed in
the pancreatic parenchyma in caerulein treated mice
(Figure 2H); decreased stromal fibrosis was observed in
caerulein treated mice administrated with sulindac diet
(Figure 2I). The stromal fibrosis highlighted by Masson
Figure 1 Experiment design and monitoring of body weight during the course of the experiment. (A) Experiment design for the
chemoprevention of sulindac on caerulein induced chronin pancreatitis in mice. (B) Monitoring of body weight during the course of
the experiment.
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lyzed and revealed that sulindac treatment significantly
lowered the fibrosis score in the pancreas comparing
with caerulein induced chronic pancreatitits mice
(1.57 ± 0.34 versus 2.43 ± 0.55, p < 0.05, Figure 3B).
Myeloperoxidase (MPO) and Mac-3 immunohisto-
chemical staining was used to label neutrophiles and
macrophages, respectively. The pancreases in control
mice exhibited no or rare MPO or Mac-3 positive cells
(Figure 2J and 2M). Numerous MPO-positive neutro-
philes and Mac-3 positive macrophages were observed
in the pancreas of caerulein induced chronic pancreatitis
mice (Figure 2K and 2N); while markedly decreased
MPO and Mac-3 positive cells were observed in sulindac
treated chronic pancreatitis mice (Figure 2L and 2O).
MPO and Mac-3 positive cells were further semi-
quantified by counting the number of positive cells per
high power field (40× objective lens), as shown in
Figure 3C, compared with caerulein induced chronic
pancreatitis mice, a significant reduction of MPO and
Mac-3 positive cells were observed in sulindac treated
chronic pancreatitis mice (MPO labeled neutrophiles:
28.6 ± 18.8 versus 86.9 ± 28.5/HPF; and Mac-3-labled
macrophages: 25.3 ± 16.7 versus 72.1 ± 21.2, The average
inflammatory cell infiltration score was 1.46 ± 0.58 ver-
sus 2.66 ± 0.75, respectively. p < 0.05).
The severity of chronic pancreatitis was further semi-
quantitatively analyzed based on the criteria for CPI with
sum of extent or areas of loss of acini, inflammatory cellinfiltration and intensity of stromal fibrosis. As shown in
Figure 3D, compared to caerulin induced chronic pan-
creatitis mice, sulindac treated mice displayed a signifi-
cant decrease of overall CPI score (4.69 ± 1.80 versus
7.42 ± 1.63, p < 0.01).
Down-regulation of inflammatory cytokines and
chemokines in chronic pancreatitis mice treated
with sulindac
Inflammatory cytokines and chemokines were further
analyzed for inflammatory activities of pancreatitis using
quantitative real-time PCR approach (n = 5/group with
both genders). As shown in Figure 4A-4B, the mRNA
levels of TNF-α and MCP-1 in the pancreatic tissue was
significantly increased in caerulein induced chronic pan-
creatitis mice compared to the control mice. Sulindac
treatment significantly lowered the expression of these
inflammatory cytokines and chemokines in chronic
pancreatitis (p < 0.05).
The fold change of mRNA expression of TGF-β,
PDGF-β and active hedgehog signaling Shh and GLI1
were also quantitated with a real-time PCR assay. As
shown in Figure 4C-F, compared to the control mice,
significantly increased Shh and GLI1mRNA expressions
were observed in the pancreatic tissues of caerulein
induced chronic pancreatitis mice (p < 0.05). More than
5 folds decrease of Shh and 2 fold decrease of GLI1
mRNA expression was found in the pancreatic tissues
of sulindac treated chronic pancreatitis mice (p < 0.05).
Figure 2 (See legend on next page.)
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Figure 2 Analysis of chronic pancreatitis using the approaches of histopathological, immunohistochemical and histochemical assay.
Histopathology in the pancreatic tissue of mice: (A) Pancreas in control mice showing morphologically normal pancreatic parenchyma (acini
and islets as well interlobular ducts). (B) Extensive chronic pancreatitis in caerulein induced chronic pancreatitis mice showing loss of acini and
stromal fibrosis. (C) Mild chronic pancreatitis in mice with sulindac treatment. Amylase and CK19 expression in the pancreas: (D) Pancreas from
control mice showing mainly composed of acinar cells and scattered islets, CK19 only positive in the ducts. (E) In caerulein induced chronic
pancreatitis mice, the amylase positive acinar cells were instead by CK19 positive ductal cells. (F) Chronic pancreatitis mice treated with sulindac
exhibiting increased amylase positive area and decreased CK19 positive area. Trichrome stain highlighting stromal fibrosis in the pancreas:
(G) Trichrome stained fibroconnective tissue (blue color) only in the interlobular areas of a normal pancreas in control mice. (H) Caerulein induced
chronic pancreatitis mice showing extensive fibrosis in pancreatic parenchyma. (I) Chronic pancreatitis mice with sulindac treatment exhibit much
less stromal fibrosis in the pancreas. MPO-labeled neutrophils in the pancreas: (J) Pancreas from control mice showed rare MPO-labeled
neutrophils. (K) Caerulein induced chronic pancreatitis mice displayed intense MPO-labeled neutrophils in the areas of pancreatitis. (L) Chronic
pancreatitis mice with sulindac treatment exhibited decreased MPO-positive neutrophils. Mac-3-labeled macrophages in the pancreas:
(M) Pancreas from control mice showed no Mac-3-labeled inflammatory cells. (N) Caerulein induced chronic pancreatitis mice displayed
intense Mac-3-labeled macrophage in the areas of pancreatitis. (O) Chronic pancreatitis mice with sulindac treatment exhibited decreased
Mac-3-positive macrophages.
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caerulein induced chronic pancreatitis mice fed with a
diet containing sulindac.
To further confirm the qPCR results, the protein level
of the above molecules were examed with western blot
assay. Similar as the results of qPCR assay, as shown in
Figure 4H, the protein expression of PDGF-β, TGF-β,
SHH and GLi1 were all up regulated in caeruleinFigure 3 Semi-quantitative analysis (histogram) of severity of chronic
showing a statistically significant difference in caerulein induced chronic pan
extent of trichrome stain-labeled stromal fibrosis revealing sulindac treatme
chronic pancreatitis mice (p < 0.05). (C) MPO and Mac3 labeled inflammatory
macrophages infiltration in the pancreas of caerulein induced chronic pancr
index (CPI) as a summary of the extent of acinar loss, stromal fibrosis and i
induced chronic pancreatitis mice treated with sulindac, comparing with theinduced chronic pancreatitis mice, significantly decreased
expression of these proteins were observed in chronic
pancreatitis mice with sulindac treatment (p < 0.05).
Oral administration of sulindac inhibits PSCs activation
as measured by α-SMA activity in chronic pancreatitis
To evaluate the activity of PSCs, the fold change of mRNA
expression of α-SMA,was quantified with a quantitivepancreatitis. (A) Amylase and CK19 positive area in the pancreas
creatitis mice with or without sulindac treatment (P < 0.05). (B) The
nt significantly decreased the extent of fibrosis in caerulein induced
cells showing a significantly decrease of neutrophils and
eatitis mice with sulindac treatment (P < 0.05). (D) Chronic pancreatitis
nflammatory cell infiltration showed significant decrease in caerulein
control mice (p < 0.05).
Figure 4 Quantitative Real-time PCR and western blot analysis of TNF- α, MCP-1, TGF-β, PDGF-β, Shh, GLI1 and α-SMA mRNA and
protein expression in the pancreas of control mice and caerulein induced chronic pancreatitis mice with or without sulindac treatment.
(A) TNF-α expression; (B) MCP-1 expression, (C) TGF-β expression, (D) PDGF-β expression, (E) SHH expression, (F) GLI1 expression and (G) α-SMA
expression (*: Statistic difference, p < 0.05). (H) Western blot results of TNF-α, MCP-1, TGF-β, PDGF-β, SHH, GLI1 and α-SMA expression, using β-
actin as loading control.
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the control mice, the mRNA expression of α-SMA was up
regulated in the pancreatic tissues of caerulein induced
chronic pancreatitis in mice, sulindac treatment markedly
decreased the expression of α-SMA at the mRNA level for
about 2 folds. The protein level of α-SMA expression was
also measured by western blot assay, and the result was
accordant with our qPCR result (Figure 4H).Figure 5 Immunohistochemical analyses of phosophorylated ERK exp
mice; (B) High intensity of p-ERK expression in caerulein induced chronic pa
induced chronic pancreatitis mice with sulindac treatment.Inhibition of MAPK signaling pathway in mice with
chronic pancreatitis treated with sulindac
Phosphorylation of ERK1/2 protein (p-ERK) as a key
molecule in ERK cascade is well detected immunohisto-
chemically. No staining signal was detected in the
pancreas in control mice (Figure 5A). Acinar-ductal meta-
plasia lesions in chronic pancreatitits were strongly stained
by the anti-p-ERK antibody in caerulein induced chronicression in chronic pancreatitis. (A) No p-ERK expression in control
ncreatitis mice; (C) Significantly decreased p-ERK expression in caerulein
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ing intensity was seen in chronic pancreatitis mice treated
with sulindac (Figure 5C).
The activity of Phosphorylation of MEK1/2 and ERK1/
2 was further analyzed quantitatively using western blot
approach. As seen in Figure 6, using total MEK1/2 and
ERK1/2 proteins as control, sulindac treatment exhibited
a significant reduction of phosphorylation of MEK1/2
and ERK1/2 proteins comparing with caerulein induced
chronic pancreatitis mice.
Discussion
Chronic pancreatitis is resulted from chronic repetitive
inflammation within the pancreas, resulting in recurrent
repair of the pancreatic damage and ultimately in activa-
tion of a profibrotic cascade [32]. In the present study,
we demonstrated that sulindac significantly inhibited
chronic pancreatitis and pancreatic fibrosis in caerulein
induced chronic pancreatitis mouse model.
Inflammatory cell infiltration (including neutrophiles,
macrophages, lymphocytes and plasma cells etc.), a com-
plex chronic active inflammatory process, is a character
of chronic pancreatitis [31]. The inflammatory cells play
a crucial role in causing tissue injury (acinar loss) and fi-
brosis either through active inflammatory cell directly
induced tissue damage or via production of oxidative
free radicals, inflammatory mediators or cytokines [26].
Our results showed that inhibition of chronic pancrea-
titis by sulindac was through a significant reduction of
myeloperoxidase-labeled neutrophils and Mac-3-positive
macrophages infiltration in the pancreas which is also
paralleled with significant decrease of pancreatic injury
as measured by amylase and cytokeratin-19 and MassonFigure 6 Western blot assay of MAPK signaling pathway in
pancreatic tissues: Sulindac treatment exhibited a significant
reduction of the phosphorylation of MEK1/2 and ERK1/2
proteins expression in the pancreatic tissues of caerulein
induced chronic pancreatitis mice.trichrome staining labeled pancreatic fibrosis. Our stud-
ies demonstrated a significant decrease of inflammatory
cells including neutrophils and macrophages infiltration
in the pancreas could be one of the key mechanisms for
chemoprevention of pancreatic inflammation and fibro-
sis by sulindac.
TNF-α is the best characterized pro-inflammatory
cytokine that is mainly secreted by macrophage [33-36],
MCP-1 is a chemokine recruits monocytes, memory T
cells, and dendritic cells to sites of tissue injury, infec-
tion, and inflammation [37]. These inflammatory media-
tors play important role in the course of inflammation.
In our experiment, the expression of these inflammatory
cytokines or mediators in the pancreas of chronic
pancreatitis mice were quantified with q-PCR assay and
showed that sulindac treatment significantly decreased
the expression of TNF-α and MCP-1 mRNA in the
pancreas. These findings imply sulindac treatment con-
tributes to the attenuation of inflammatory cell infil-
tration by reducing these key inflammatory mediators
and cytokines.
Fibrosis and desmoplasia are the characters of chronic
pancreatitis and pancreatic stellate cells play a crucial
role in pancreatic fibrogenesis in chronic pancreatitis
[7]. Aoki et al. found that COX-2 is constitutively
expressed in activated PSCs, and COX-2 inhibitors
blocked the activation of quiescent PSCs and upregula-
tion of α-SMA expression in vitro, indicating that COX-
2 is important in the initiation and promotion of PSC
activation [20]. The expression of α-SMA, which indicats
the activation of PSCs was significantly upregulated in
the chronic pancreatitis mice in our study, sulindac treat-
ment resulted a marked reduction of α-SMA expression,
implying that targeting the PSCs could be one of the key
mechanisms for the anti-fibrogenic effect of sulindac.
TGF-β and PDGF-β, liberated by inflammatory cells,
have been shown to have significant impact on the activ-
ity of PSCs [3]. In our experiment, the expression of pro-
fibrogenic inflammatory cytokines TGF-β and PDGF-β
were upregulated in caerulein induced chronic pancrea-
titis, and a reduction of TGF-β and PDGF-β expression
were found with sulindac treatment. Although the
decrease of TGF-β and PDGF-β mRNA expression in
caerulein induced chronic pancreatitis mice fed with
sulindac diet did not reach statistical significance, the
protein expression of TGF-β and PDGF-β were upregu-
lated in chronic pancreatitis mice and sulindac treatment
significantly decreased TGF-β and PDGF-β expression at
the protein level. Therefore, the attenuation of profibro-
tic inflammatory cytokines TGF-β and PDGF-β could
be a mechanism for the regulation of PSCs activation
by sulindac.
The expression of Shh/GLI activity was also signifi-
cantly increased in the pancreas of caerulein induced
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showed a markedly down regulation of Shh and GLI1
mRNA and protein expression, implying that targeting
Shh/GLI pathway by sulindac could be a mechanism for
inhibiting pancreatic fibrosis and desmoplasia in chronic
pancreatitis. Our results imply that the aberrant Shh/
GLI1 pathway could be involved in pancreatic desmopla-
sia in caerulein induced chronic pancreatitis.
A major pathway for regulation of the progression of
chronic inflammation and fibrosis in chronic pancreatitis
is extracellular signal related kinase (ERK1/2) pathway
that is related to mitogen-activated protein kinase
(MAPK) [38]. In this study, using immunohistochemical
and Western blot approach, we found that sulindac
treatment inhibit the phosphorylation of MEK and ERK,
the key molecules in MAPK signaling pathway which
plays a pivotal role in the activation of cellular processes
such as proliferation, differentiation, and oncogenic
transformation. This result indicated that the inhibition
of chronic pancreatitis and consequent pancreatic car-
cinogenesis by sulindac maybe by targeting the ERK/
MAPK signaling pathway.
Conclusions
Taken together, we provide the evidence that sulindac
exhibits strong activity against inflammation and fibrosis
in the context of chronic pancreatitis in mice via block-
ing inflammatory cell infiltration and the activation of
pancreatic satellet cells. EKR/MAPK signaling pathways
may be influenced in reduced chronic inflammation and
fibrosis. Sulindac is a very promising reagent for inhibit-
ing chronic pancreatitis and will have a high potential to
translate into clinical trial in future for the chemopre-
vention of chronic pancreatitis and its associated pancre-
atic carcinogenesis.
Abbreviations
CP: chronic pancreatitis; ROS: reactive oxygen species; RONS: nitrogen
species; AA: arachidonic Acid; NSAIDs: non-steroidal anti-inflammatory
drugs; COX: cyclooxygenase; PG: prostaglandin; IACUC: Institutional
Animal Care and Use Committee; IP: intraperitoneal; CPI: chronic pancreatitis
index; MPO: myeloperoxidase; ERK: Extracellular signal-regulated kinases;
DAB: 3, 3-diaminobenzidine; AEC: 3-amino-9-ethylcarbazole; TNF-α:
tumor necrosis factor α; MCP-1: monocyte chemotactic protein 1;
TGF-β: transforming growth factor β; PDGF-β: platelet derived growth factor
β; Shh: sonic hedgehog homolog; GLI1: glioma-associated oncogene
homolog 1; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase;
DEPC: diethylprocarbonate; PVDF: polyvinylidene fluoride; BSA: bovine serum
albumin; TBST: Tris-buffered saline with 0.1% Tween-20; MEK: MAP kinase
kinase; HRP: horseradish peroxidase; RT: room temperature; CK19: cytokeratin
19; HPF: high power field; MAPK: Mitogen-activated protein kinases.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HB and XGD designed, executed and coordinated of the studies. HB, XKC
and LZ carried out the experiments, HB and XKC drafted the manuscript and
XGD supervised the draft of the manuscript. All authors read and approved
the final manuscript.Acknowledgement
We thank Dr. Guang-yu Yang and Dr. Jie Liao, Department of pathology,
Feinberg school of Medicine, Northwestern University for their support to
the experiments and critical review and valuable advices to the manuscript.
Author details
1Department of Infectious Disease, Shengjing Hospital of China Medical
University, Shenyang 110004, China. 2Department of Surgery, Shengjing
Hospital of China Medical University, Shenyang 110004, China.
Received: 30 March 2012 Accepted: 2 August 2012
Published: 24 August 2012
References
1. Reding T, et al: A selective COX-2 inhibitor suppresses chronic
pancreatitis in an animal model (WBN/Kob rats): significant reduction of
macrophage infiltration and fibrosis. Gut 2006, 55(8):1165–1173.
2. Ulmasov B, et al: Angiotensin II signaling through the AT1a and AT1b
receptors does not have a role in the development of cerulein-induced
chronic pancreatitis in the mouse. Am J Physiol Gastrointest Liver Physiol
2010, 299(1):G70–G80.
3. Shimizu K: Mechanisms of pancreatic fibrosis and applications to the
treatment of chronic pancreatitis. J Gastroenterol 2008, 43(11):823–832.
4. Charrier AL, Brigstock DR: Connective tissue growth factor production by
activated pancreatic stellate cells in mouse alcoholic chronic
pancreatitis. Lab Invest 2010, 90(8):1179–1188.
5. Phillips PA, et al: Cell migration: a novel aspect of pancreatic stellate cell
biology. Gut 2003, 52(5):677–682.
6. Mews P, et al: Pancreatic stellate cells respond to inflammatory cytokines:
potential role in chronic pancreatitis. Gut 2002, 50(4):535–541.
7. Talukdar R, Tandon RK: Pancreatic stellate cells: new target in the
treatment of chronic pancreatitis. J Gastroenterol Hepatol 2008,
23(1):34–41.
8. Yang L, et al: L-cysteine administration attenuates pancreatic fibrosis
induced by TNBS in rats by inhibiting the activation of pancreatic
stellate cell. PLoS One 2012, 7(2):e31807.
9. Kayed H, et al: Distribution of Indian hedgehog and its receptors patched
and smoothened in human chronic pancreatitis. J Endocrinol 2003,
178(3):467–478.
10. Shinozaki S, et al: Indian hedgehog promotes the migration of rat
activated pancreatic stellate cells by increasing membrane type-1 matrix
metalloproteinase on the plasma membrane. J Cell Physiol 2008,
216(1):38–46.
11. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular,
and molecular biology. Annu Rev Biochem 2000, 69:145–182.
12. Schlosser W, et al: Cyclooxygenase-2 is overexpressed in chronic
pancreatitis. Pancreas 2002, 25(1):26–30.
13. Silva A, et al: COX-2 is not required for the development of murine
chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 2011,
300(6):G968–G975.
14. Polito F, et al: Flavocoxid, a dual inhibitor of cyclooxygenase-2 and
5-lipoxygenase, reduces pancreatic damage in an experimental model
of acute pancreatitis. Br J Pharmacol 2010, 161(5):1002–1011.
15. Marshall TM, et al: Activation of descending pain-facilitatory pathways
from the rostral ventromedial medulla by cholecystokinin elicits release
of prostaglandin-E(2) in the spinal cord. Pain 2012, 153(1):86–94.
16. Masuko K, et al: Prostaglandin E2 regulates the expression of connective
tissue growth factor (CTGF/CCN2) in human osteoarthritic chondrocytes
via the EP4 receptor. BMC Res Notes 2010, 3:5.
17. Chan MM, Moore AR: Resolution of inflammation in murine autoimmune
arthritis is disrupted by cyclooxygenase-2 inhibition and restored by
prostaglandin E2-mediated lipoxin A4 production. J Immunol 2010,
184(11):6418–6426.
18. Roberts HR, et al: Colon tumour cells increase PGE(2) by regulating COX-2
and 15-PGDH to promote survival during the microenvironmental stress
of glucose deprivation. Carcinogenesis 2011, 32(11):1741–1747.
19. Hasan S, et al: Expression analysis of the prostaglandin E2 production
pathway in human pancreatic cancers. Pancreas 2008, 37(2):121–127.
20. Aoki H, et al: Cyclooxygenase-2 is required for activated pancreatic
stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell
Physiol 2007, 292(1):C259–C268.
Bai et al. BMC Gastroenterology 2012, 12:115 Page 11 of 11
http://www.biomedcentral.com/1471-230X/12/11521. Seo SW, et al: Selective cyclooxygenase-2 inhibitor ameliorates
cholecystokinin-octapeptide-induced acute pancreatitis in rats. World J
Gastroenterol 2007, 13(16):2298–2304.
22. Haanen C: Sulindac and its derivatives: a novel class of anticancer
agents. Curr Opin Investig Drugs 2001, 2(5):677–683.
23. Willemer S, Elsasser HP, Adler G: Hormone-induced pancreatitis. Eur Surg
Res 1992, 24(Suppl 1):29–39.
24. Yoo BM, et al: Novel antioxidant ameliorates the fibrosis and
inflammation of cerulein-induced chronic pancreatitis in a mouse model.
Pancreatology 2005, 5(2–3):165–176.
25. Aghdassi AA, et al: Animal models for investigating chronic pancreatitis.
Fibrogenesis Tissue Repair 2011, 4(1):26.
26. Neuschwander-Tetri BA, et al: Repetitive self-limited acute pancreatitis
induces pancreatic fibrogenesis in the mouse. Dig Dis Sci 2000,
45(4):665–674.
27. Su KH, Cuthbertson C, Christophi C: Review of experimental animal
models of acute pancreatitis. HPB (Oxford) 2006, 8(4):264–286.
28. Mahmoud NN, et al: The sulfide metabolite of sulindac prevents tumors
and restores enterocyte apoptosis in a murine model of familial
adenomatous polyposis. Carcinogenesis 1998, 19(1):87–91.
29. Bai H, et al: Inhibition of chronic pancreatitis and pancreatic
intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre
mice. Carcinogenesis 2011, 32(11):1689–1696.
30. Seril DN, et al: Inhibition of chronic ulcerative colitis-associated colorectal
adenocarcinoma development in a murine model by N-acetylcysteine.
Carcinogenesis 2002, 23(6):993–1001.
31. Tandon RK, Garg PK: Oxidative stress in chronic pancreatitis:
pathophysiological relevance and management. Antioxid Redox Signal
2011, 15(10):2757–2766.
32. van Westerloo DJ, et al: Therapeutic effects of troglitazone in
experimental chronic pancreatitis in mice. Am J Pathol 2005,
166(3):721–728.
33. Wang X, Lin Y: Tumor necrosis factor and cancer, buddies or foes? Acta
Pharmacol Sin 2008, 29(11):1275–1288.
34. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to
cancer development and progression. Nat Rev Immunol 2005,
5(10):749–759.
35. Grivennikov SI, Karin M: Inflammation and oncogenesis: a vicious
connection. Curr Opin Genet Dev 2010, 20(1):65–71.
36. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer.
Cell 2010, 140(6):883–899.
37. Carr MW, et al: Monocyte chemoattractant protein 1 acts as a
T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994,
91(9):3652–3656.
38. Masamune A, et al: Differential roles of signaling pathways for
proliferation and migration of rat pancreatic stellate cells. Tohoku J Exp
Med 2003, 199(2):69–84.
doi:10.1186/1471-230X-12-115
Cite this article as: Bai et al.: The effect of sulindac, a non-steroidal
anti-inflammatory drug, attenuates inflammation and fibrosis in a
mouse model of chronic pancreatitis. BMC Gastroenterology 2012 12:115.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
